Alkermes today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461, a novel, once-daily, oral investigational medicine... read more
Alkermes today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461, a novel, once-daily, oral investigational medicine... read more
AstraZeneca and Merck today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for Lynparza in metastatic breast cancer. The trial compared Lynparza ... read more
Merck today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Study... read more
DNAtix has completed the first Proof Of Concept (POC) test by transferring the complete genome sequence of a virus - Enterobacteria phage phiX174 sensu lato - over the Ethereum Blockchain. The... read more
NGM Bio today announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological measures of disease in nonalcoholic... read more